Tofacitinib Prodrug-1

Tofacitinib precursor-1 is an effective and oral active precursor to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib precursor-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib precursor-1 is a potential drug candidate for the research of ulcerative colitis[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; JAK

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tofacitinib-prodrug-1.html

Solubility

10 mM in DMSO

Smiles

O=C(O)C1=CC(/N=N/C2=CC=C(COC(NCCCN(C)C(N3C=CC4=C(NC[C@@H]5CN(C(CC#N)=O)CC[C@H]5C)N=CN=C43)=O)=O)C(Cl)=C2)=CC=C1O

Molecular Formula

C36H39ClN10O7

Molecular Weight

759.21

References & Citations

[1]Zhao J, et al. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem. 2022;65 (6) :4926-4948.